173 related articles for article (PubMed ID: 35948758)
21. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.
Becker K; Pancoska P; Concin N; Vanden Heuvel K; Slade N; Fischer M; Chalas E; Moll UM
Int J Oncol; 2006 Oct; 29(4):889-902. PubMed ID: 16964385
[TBL] [Abstract][Full Text] [Related]
22. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
23. Physical and functional interaction between p53 mutants and different isoforms of p73.
Strano S; Munarriz E; Rossi M; Cristofanelli B; Shaul Y; Castagnoli L; Levine AJ; Sacchi A; Cesareni G; Oren M; Blandino G
J Biol Chem; 2000 Sep; 275(38):29503-12. PubMed ID: 10884390
[TBL] [Abstract][Full Text] [Related]
24. [The coordinated interaction of multifunctional members of p53 family determines many key processes in multicellular organisms].
Vilgelm AE; Zaika AI; Prasolov VS
Mol Biol (Mosk); 2011; 45(1):180-97. PubMed ID: 21485507
[TBL] [Abstract][Full Text] [Related]
25. TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.
Costanzo A; Pediconi N; Narcisi A; Guerrieri F; Belloni L; Fausti F; Botti E; Levrero M
FEBS Lett; 2014 Aug; 588(16):2590-9. PubMed ID: 24983500
[TBL] [Abstract][Full Text] [Related]
26. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.
Hassan HM; Dave BJ; Singh RK
Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526
[TBL] [Abstract][Full Text] [Related]
27. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
28. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
[TBL] [Abstract][Full Text] [Related]
29. Regulation of p73 activity by post-translational modifications.
Conforti F; Sayan AE; Sreekumar R; Sayan BS
Cell Death Dis; 2012 Mar; 3(3):e285. PubMed ID: 22419114
[TBL] [Abstract][Full Text] [Related]
30. From p63 to p53 across p73.
Strano S; Rossi M; Fontemaggi G; Munarriz E; Soddu S; Sacchi A; Blandino G
FEBS Lett; 2001 Feb; 490(3):163-70. PubMed ID: 11223031
[TBL] [Abstract][Full Text] [Related]
31. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
[TBL] [Abstract][Full Text] [Related]
32. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.
Stiewe T; Theseling CC; Pützer BM
J Biol Chem; 2002 Apr; 277(16):14177-85. PubMed ID: 11844800
[TBL] [Abstract][Full Text] [Related]
33. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
34. Promoter specificity and stability control of the p53-related protein p73.
Lee CW; La Thangue NB
Oncogene; 1999 Jul; 18(29):4171-81. PubMed ID: 10435630
[TBL] [Abstract][Full Text] [Related]
35. p73 as a pharmaceutical target for cancer therapy.
Bisso A; Collavin L; Del Sal G
Curr Pharm Des; 2011; 17(6):578-90. PubMed ID: 21391908
[TBL] [Abstract][Full Text] [Related]
36. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity.
Ory B; Ellisen LW
Oncotarget; 2011 Mar; 2(3):259-64. PubMed ID: 21436470
[TBL] [Abstract][Full Text] [Related]
37. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.
Hong B; Prabhu VV; Zhang S; van den Heuvel AP; Dicker DT; Kopelovich L; El-Deiry WS
Cancer Res; 2014 Feb; 74(4):1153-65. PubMed ID: 24247721
[TBL] [Abstract][Full Text] [Related]
38. [TAp73α is Upregulated in the Most Common Human Cancers].
Iscan E; Karakülah G; Ekin U; Ozturk M; Uzuner H; Suner A
Mol Biol (Mosk); 2022; 56(2):320. PubMed ID: 35403622
[TBL] [Abstract][Full Text] [Related]
39. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.
Marcel V; Dichtel-Danjoy ML; Sagne C; Hafsi H; Ma D; Ortiz-Cuaran S; Olivier M; Hall J; Mollereau B; Hainaut P; Bourdon JC
Cell Death Differ; 2011 Dec; 18(12):1815-24. PubMed ID: 21941372
[TBL] [Abstract][Full Text] [Related]
40. Structural diversity of p63 and p73 isoforms.
Osterburg C; Dötsch V
Cell Death Differ; 2022 May; 29(5):921-937. PubMed ID: 35314772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
